0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Non-Hodgkin’s Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2028
Published Date: March 2019
|
Report Code: DELV-Mark-229
Home | Market Reports | Health | Health Conditions
Non Hodgkins Lymphoma Market Insight Epidemiology and Market Forecast 2028

Non-Hodgkin’s Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2028

Code: DELV-Mark-229
Report
March 2019
100 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Non-Hodgkin’s Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Non-Hodgkin’s Lymphoma (NHL) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Non-Hodgkin’s Lymphoma (NHL) Understanding and Treatment Algorithm
The market report provides the overview of the Non-Hodgkin’s Lymphoma (NHL) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Non-Hodgkin’s Lymphoma (NHL) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Non-Hodgkin’s Lymphoma (NHL) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Non-Hodgkin’s Lymphoma (NHL) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Non-Hodgkin’s Lymphoma (NHL) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Non-Hodgkin’s Lymphoma (NHL) market.

Non-Hodgkin’s Lymphoma (NHL) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Non-Hodgkin’s Lymphoma (NHL) Report Insights
• Patient Population in Non-Hodgkin’s Lymphoma (NHL)
• Therapeutic Approaches in Non-Hodgkin’s Lymphoma (NHL)
• Non-Hodgkin’s Lymphoma (NHL) Pipeline Analysis
• Non-Hodgkin’s Lymphoma (NHL) Market Size and Trends
• Non-Hodgkin’s Lymphoma (NHL) Market Opportunities
• Impact of upcoming Therapies in Non-Hodgkin’s Lymphoma (NHL)

Non-Hodgkin’s Lymphoma (NHL) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Non-Hodgkin’s Lymphoma (NHL) Report Assessment
• Current Treatment Practices in Non-Hodgkin’s Lymphoma (NHL)
• Unmet Needs in Non-Hodgkin’s Lymphoma (NHL)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Non-Hodgkin’s Lymphoma (NHL) market
• Organize sales and marketing efforts by identifying the best opportunities for Non-Hodgkin’s Lymphoma (NHL) market
• To understand the future market competition in the Non-Hodgkin’s Lymphoma (NHL) market.

1. Report Introduction
2. Non-Hodgkin’s Lymphoma (NHL) Market Overview at a Glance
2.1. Market Share Distribution of Non-Hodgkin’s Lymphoma (NHL) in 2016
2.2. Market Share Distribution of Non-Hodgkin’s Lymphoma (NHL) in 2028
3. Disease Background and Overview: Non-Hodgkin’s Lymphoma (NHL)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Non-Hodgkin’s Lymphoma (NHL) in 7MM
4.3. Total Prevalent Patient Population of Non-Hodgkin’s Lymphoma (NHL) in 7MM – By Countries
5. Epidemiology of Non-Hodgkin’s Lymphoma (NHL) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.1.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.1.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.1.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.1.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.4.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.4.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.4.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.4.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.5.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.5.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.5.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.5.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.6.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.6.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.6.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.6.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.7.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.7.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.7.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.7.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.8.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.8.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.8.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.8.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.9.3. Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.9.4. Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) *
5.9.5. Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL)
5.9.6. Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Non-Hodgkin’s Lymphoma (NHL)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Non-Hodgkin’s Lymphoma (NHL)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Non-Hodgkin’s Lymphoma (NHL) : 7MM Market Analysis
12.1. 7MM Market Size of Non-Hodgkin’s Lymphoma (NHL)
12.2. 7MM Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL)
12.3. 7MM Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products
13. Non-Hodgkin’s Lymphoma (NHL) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in United States
13.1.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in United States
13.1.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in Germany
13.2.1.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in Germany
13.2.1.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in France
13.2.2.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in France
13.2.2.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in Italy
13.2.3.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in Italy
13.2.3.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in Spain
13.2.4.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in Spain
13.2.4.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in United Kingdom
13.2.5.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Non-Hodgkin’s Lymphoma (NHL) in Japan
13.3.2. Percentage Share of drugs marketed for Non-Hodgkin’s Lymphoma (NHL) in Japan
13.3.3. Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

LIST OF TABLES :

Table 1: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM
Table 2: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 6: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 7: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 12: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 15: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 16: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 17: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 22: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 27: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 31: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 32: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Table 37: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 42:7MM- Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 45: United States-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 48: Germany-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 51: France-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 54: Italy-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 57: Spain-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 60:UK-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Table 63: Japan-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)

LIST OF FIGURES :

Figure 1: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 7: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 12: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 16: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 17: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 22: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 27: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 32: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Figure 37: Treatable Cases of the Non-Hodgkin’s Lymphoma (NHL) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 42:7MM- Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 45: United States-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 48: Germany-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 51: France-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 54: Italy-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 57: Spain-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 60:UK-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Non-Hodgkin’s Lymphoma (NHL) in USD MM (2016-2028)
Figure 63: Japan-Market Share Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Non-Hodgkin’s Lymphoma (NHL) by Therapies in USD MM (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Samsung SD

RELATED REPORTS

Global Cardiac Monitoring Products Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Cardiac Monitoring Products Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10A290
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and United States Radiation Oncology Market Size Status and Forecast 2021 2027
Global and United States Radiation Oncology Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18B3286
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and China Glucose Meters Market Insights Forecast to 2027
Global and China Glucose Meters Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-13W3412
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global Coronary Atherectomy Devices Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Coronary Atherectomy Devices Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

In 2020 the global Coronary Atherectomy Devices market size was US 240 million and it is expected to reach US 375.6 million by the end of 2027 with a CAGR of 6.6 during 20212027.Global Coronary Atherectomy Devices Market Size Manufacturers Supply Chain Sales Channel and Clients 20212027.

120 Pages
Type: Report
Code: QYRE-Auto-12P242
Mon Sep 27 00:00:00 UTC 2021

Add to Cart